• Acquisition of Amplia Therapeutics - Questions & Answers

    More +
  • CEO announces focus on Immuno-Oncology and Acquisition of 2 Cancer Drug Candidates

    More +
  • Contact Us

    Contact us for help, support or advice.

    More +

Welcome to Innate Immunotherapeutics

Innate Immunotherapeutics Limited (ASX: IIL) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Innate has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).